ITP Support Association/LinkedIn
Aug 10, 2026, 13:36
Ianalumab and the Changing Landscape of ITP Treatment – ITP Support Association
ITP Support Association shared a post on LinkedIn:
“We asked Tung Le at Imperial College Hammersmith Hospital what Novartis have been working on. The answer: Ianalumab, studied across four trials between 2023 and 2025, each looking at a different stage of ITP:
- First-line – newly diagnosed patients, started within 28 days of diagnosis
- Second-line – patients who hadn’t responded to first-line therapy
- Refractory – patients who’d already been through multiple lines of treatment
Recruitment for these particular trials has now closed, but patients who took part are still being followed up, some for two to three years so far, helping researchers understand the longer-term picture.
Research like this is how new treatment options eventually make their way to patients. Curious what’s currently recruiting?
We keep an up-to-date list on our website.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 09:18Shamee Shastry: How Transfusion Medicine Research Is Evolving in India
-
Sep 22, 2026, 09:11Tarique Shahzad Chachar: Why Warfarin Remains the Gold Standard for Mechanical Heart Valves
-
Sep 22, 2026, 09:04Bianca Rocca: Thromboinflammatory Injury in Ischemic Limb Necrosis During Severe Shock
-
Sep 22, 2026, 09:01Ash Paul: Comparing Left Atrial Appendage Occlusion and Oral Anticoagulation
-
Sep 22, 2026, 08:50Emily Horner: Lipoprotein(a) Links Oxidized Phospholipids to Platelet Hyperactivity
-
Sep 22, 2026, 08:42Sally Mandour: Bone Marrow Needle Gauge Explained
-
Sep 22, 2026, 08:39Alessandro Sionis: Navigating Anticoagulation in Mechanical Circulatory Support
-
Sep 22, 2026, 08:28Raghavendra Rao: The Latest Research on Varicose Veins
-
Sep 22, 2026, 08:23Aravind Palraj: Three Essential Tests in Antiphospholipid Syndrome